Before, we told you to delete your data because 23andMe was about to be sold. Now, a buyer has been announced, and they’re ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced today that it will acquire 23andMe for a purchase price of $256 ...

The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...

Regeneron to rescue 23andMe in a $256 million deal, raising major questions about DNA privacy, genetic data ownership, and ...

Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Adam Kovalčík, 19, of Dulovce, Slovakia, ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices ...

Regeneron Pharmaceuticals enters into asset purchase agreement to acquire 23andMe for $256 million: Tarrytown, New York Wednesday, May 21, 2025, 13:00 Hrs [IST] Regeneron Pharmace ...

In this week’s edition of InnovationRx, we look at the FDA's new rules on Covid-19 vaccines, Novartis’s acquisition strategy, ...

SAN FRANCISCO, (GLOBE NEWSWIRE) --  23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a ...

Regeneron's lead counsel was Jonathan D. Polkes of White & Case LLP.

Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also ...